OBJECTIVE: To evaluate the efficacy and @entity137 of domestic recombinant @entity1 @entity4382 ( @entity8033 ) in the prevention of chemotherapy-induced @entity882 . METHODS: A randomized, self-crossover and placebo-controlled trial was conducted, with @entity8033 and placebo classified randomly as drug A and drug B. @entity1 were randomly assigned to group AB or group BA. 25 microg/kg body weight of drug A or drug B was administered subcutaneously once daily starting 24 hours after chemotherapy and continued for 7 to 14 days or until the platelet count reached > or = 300 x 10(9)/L. RESULTS: 118 @entity1 were evaluable in the efficacy study. When compared with the placebo treated cycle, the results showed that @entity8033 was able to significantly increase the platelet count at the nadir and d21 after chemotherapy, with a increase of 60.7% and 86.1% (both P < 0.001). The mean duration of @entity882 (< 100 x 10(9)/L) in @entity8033 treated cycle was 1.0 +/- 2.0 days as compared to 6.9 +/- 5.3 days in placebo treated cycle. The side effects were ache (24.6%), swelling (16.1%) and knurl (11.9%) at the injection site, hyperaemia of conjunctiva (16.1%), @entity4 (8.5%), palpitation (6.8%) and @entity1295 (5.1%). CONCLUSION: @entity8033 , possessing significant thrompoietic activity, significantly increases the likelihood of avoiding chemotherapy-induced @entity882 and shorten the duration of @entity882 . Its side effects are mild and manageable.

[Recombinant @entity1 @entity4382 in the prevention of chemotherapy-induced XXXX ].

@entity1 :: ('9606', 'Species') :: ['Patients', 'human', 'patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity4382 :: ('3589', 'Gene') :: ['interleukin-11'] @entity4 :: ('MESH:D004487', 'Disease') :: ['edema'] @entity8033 :: ('MESH:C105308', 'Chemical') :: ['rhIL-11'] @entity1295 :: ('MESH:D005221', 'Disease') :: ['fatigue']
@entity882 :: (MESH:D013921,Disease) :: ['thrombocytopenia']
